MX353186B - Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. - Google Patents

Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Info

Publication number
MX353186B
MX353186B MX2014012257A MX2014012257A MX353186B MX 353186 B MX353186 B MX 353186B MX 2014012257 A MX2014012257 A MX 2014012257A MX 2014012257 A MX2014012257 A MX 2014012257A MX 353186 B MX353186 B MX 353186B
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
methods
diagnosing
treating
monitoring rheumatoid
Prior art date
Application number
MX2014012257A
Other languages
English (en)
Inventor
Flavius Martin
Jr Glynn Dennis
Michael J Townsend
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX353186B publication Critical patent/MX353186B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a un método para predecir la respuesta de un sujeto a un agente terapéutico de RA, que comprende medir en una muestra biológica del sujeto la expresión de uno o una combinación de genes o la expresión de una o una combinación de proteínas codificadas por uno o una combinación de genes, en donde el uno o la combinación de genes comprende ICAM1 y CXCL13, en donde la expresión diferencial de la combinación de genes, o la expresión diferencial de la combinación de proteínas, predice la respuesta del sujeto al agente terapéutico RA.
MX2014012257A 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. MX353186B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27594809P 2009-09-03 2009-09-03
US25242409P 2009-10-16 2009-10-16
PCT/US2010/047734 WO2011028945A1 (en) 2009-09-03 2010-09-02 Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX353186B true MX353186B (es) 2018-01-05

Family

ID=43625246

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012002766A MX2012002766A (es) 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
MX2014012257A MX353186B (es) 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012002766A MX2012002766A (es) 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Country Status (12)

Country Link
US (2) US8728730B2 (es)
EP (2) EP2473637B1 (es)
JP (3) JP5996429B2 (es)
KR (1) KR20120104517A (es)
CN (2) CN107385034B (es)
BR (1) BR112012004777A2 (es)
CA (1) CA2772929A1 (es)
HK (1) HK1245341A1 (es)
IN (1) IN2012DN02485A (es)
MX (2) MX2012002766A (es)
RU (2) RU2539112C2 (es)
WO (1) WO2011028945A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1692182T3 (pl) * 2003-11-05 2010-09-30 Roche Glycart Ag Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2772929A1 (en) 2009-09-03 2011-03-11 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
AU2011207253B2 (en) 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
RU2012139181A (ru) 2010-02-26 2014-04-10 Ново Нордиск А/С Стабильная композиция, содержащая антитело
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
CA2819038C (en) 2010-12-06 2023-10-17 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
JP5885926B2 (ja) * 2011-01-28 2016-03-16 シスメックス株式会社 関節リウマチの存在の評価方法およびその方法に用いられるバイオマーカーセット
BR112013021725A2 (pt) * 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
WO2012167186A1 (en) * 2011-06-02 2012-12-06 Health Datastream Inc. System and method for scoring illness complexity to predict healthcare cost
EP2773669B1 (en) 2011-11-04 2018-03-28 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
MX2014009490A (es) 2012-02-10 2014-08-29 Novo Nordisk As Metodos relacionados con el tratamiento de enfermedades y trastornos inflamatorios.
WO2013135789A1 (en) * 2012-03-15 2013-09-19 Universiteit Hasselt Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014028374A1 (en) * 2012-08-17 2014-02-20 Eli Lilly And Company Biomarkers predictive of rheumatoid arthritis or systemic lupus erythematosus response to anti-baff antibody therapy
EP2951586A1 (en) * 2013-01-31 2015-12-09 The University of Birmingham Biomarkers of autoimmune and/or chronic diseases associated with joint inflammation
EP2813850A1 (en) * 2013-06-10 2014-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting rheumatoid arthritis treatment response
KR101664964B1 (ko) * 2013-06-21 2016-10-11 가톨릭대학교 산학협력단 류마티스 관절염 진단용 바이오마커
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
CN103399147B (zh) * 2013-08-07 2015-06-17 苏州大学 多聚半乳糖醛酸的新应用
KR101628035B1 (ko) * 2013-09-13 2016-06-09 인제대학교 산학협력단 Ｖｓｉｇ４를 이용한 난소암 치료제 스크리닝 방법
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
EP2863231A1 (en) * 2013-10-17 2015-04-22 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter
ES2824108T3 (es) 2014-03-12 2021-05-11 Icahn School Med Mount Sinai Método para identificar receptores de aloinjertos de riñón en riesgo de lesión crónica
RU2554755C1 (ru) * 2014-05-26 2015-06-27 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Способ диагностики ревматоидного артрита
EP3161165B1 (en) 2014-06-26 2020-11-18 Icahn School of Medicine at Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets, therapeutic agent for use in the treatment and kits for determining the expression
KR20160048442A (ko) * 2014-10-24 2016-05-04 가톨릭대학교 산학협력단 류마티스 관절염 관련 바이오마커
US20180024142A1 (en) * 2015-01-29 2018-01-25 Ares Trading S.A. Immunoassays for high positively charged proteins
CN105988009B (zh) * 2015-02-28 2018-03-13 复旦大学附属华山医院 Netrin‑4在制备检测胃癌及预后标志物的制剂中的用途
WO2016154553A1 (en) * 2015-03-25 2016-09-29 La Jolla Institute For Allergy And Immunology Cxcl13 as an indicator of germinal center activity and immune response
JP6663000B2 (ja) * 2015-05-12 2020-03-11 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル 関節リウマチの診断のための自己抗原
UA124615C2 (uk) 2015-06-16 2021-10-20 Дженентек, Інк. АНТИТІЛО ПРОТИ ПОДІБНОГО ДО Fc-РЕЦЕПТОРА БІЛКА 5 (FcRH5)
CN105200159B (zh) * 2015-11-06 2018-06-15 北京致成生物医学科技有限公司 骨性关节炎诊疗试剂及其应用
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
WO2017181038A1 (en) * 2016-04-15 2017-10-19 Rowan University Serum biomarkers for predicting and evaluating response to tnf inhibitor therapy in rheumatoid arthritis patients
US20170321286A1 (en) * 2016-05-05 2017-11-09 Exact Sciences Corporation Detection of lung neoplasia by amplification of rna sequences
EP3463441B1 (en) 2016-06-07 2023-10-25 The General Hospital Corporation Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis
RU2622597C1 (ru) * 2016-07-05 2017-06-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ прогнозирования суставного болевого синдрома у пациентов с признаками дисплазии соединительной ткани
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
CN106526196B (zh) * 2016-10-08 2018-08-10 北京大学人民医院 Sr-a作为类风湿关节炎诊断标志物及干预靶点的应用
EP3539978A4 (en) * 2016-11-09 2020-08-05 ICM Co., Ltd. NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION WITH IT AS THE ACTIVE INGREDIENT
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR102588627B1 (ko) 2017-03-08 2023-10-16 김성진 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
WO2018164507A2 (ko) * 2017-03-08 2018-09-13 주식회사 길로 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
US11325969B2 (en) * 2017-08-29 2022-05-10 Veritas Therapeutics Inc. FGL2 antibodies and binding fragments thereof and uses thereof
EP3513280A4 (en) * 2017-11-13 2020-07-22 The Multiple Myeloma Research Foundation, Inc. INTEGRATED, MOLECULAR, OMIC, IMMUNOTHERAPY, METABOLIC, EPIGENETIC AND CLINICAL DATABASE
WO2019147779A1 (en) * 2018-01-24 2019-08-01 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
CN108359726B (zh) * 2018-02-28 2020-09-04 固安博健生物技术有限公司 Coro2b作为分子诊治标志物的用途
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
US11572589B2 (en) 2018-04-16 2023-02-07 Icahn School Of Medicine At Mount Sinai Method for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190359985A1 (en) * 2018-05-22 2019-11-28 John Lawrence Mee Adjustable method for sustainable human cognitive enhancement
CN109142729B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-hmgb3自身抗体及其应用
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement
US10723191B1 (en) 2018-07-01 2020-07-28 Softwheel Ltd. In-wheel three-arm suspension for vehicles
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途
WO2020082090A1 (en) * 2018-10-19 2020-04-23 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
CN109207584A (zh) * 2018-11-01 2019-01-15 固安博健生物技术有限公司 Marco作为早期诊断骨关节炎的分子标志物的应用
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
SG11202112021QA (en) 2019-05-08 2021-11-29 Janssen Biotech Inc Materials and methods for modulating t cell mediated immunity
AU2020308906A1 (en) 2019-06-27 2022-02-03 Scipher Medicine Corporation Developing classifiers for stratifying patients
CN114573663B (zh) * 2019-08-27 2023-08-11 广东菲鹏生物有限公司 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒
CN110408590B (zh) * 2019-09-06 2022-10-25 遵义医学院附属医院 一种诱导人间充质干细胞向成骨细胞分化的方法与应用
GB201914079D0 (en) * 2019-09-30 2019-11-13 Univ London Queen Mary Method of predicting requirement for biologic therapy
KR102596937B1 (ko) * 2019-11-07 2023-11-03 가톨릭대학교 산학협력단 류마티스 관절염의 판누스 진단용 바이오마커 및 이의 이용
CN111091909B (zh) * 2019-11-26 2022-05-31 中国信息通信研究院 一种医学影像识别方法和装置
CN113122628B (zh) * 2019-12-30 2023-08-11 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Clec5a基因作为标志物在子宫内膜癌中诊断及治疗的应用
CN112114126B (zh) * 2020-08-13 2023-03-24 川北医学院 一种系统性红斑狼疮的诊断标志物及其应用
WO2022064163A1 (en) * 2020-09-22 2022-03-31 The Secretary Of State For Defence Apparatus, kits and methods for predicting the development of sepsis
CN112646887B (zh) * 2020-12-23 2023-02-28 广州医科大学附属第五医院 Znf239作为肝癌诊治的靶标
CN112946269B (zh) * 2020-12-29 2022-12-27 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Abca1与cd68作为预后标记物在制备肝癌预后预测试剂盒中的应用
CN113186281B (zh) * 2021-04-02 2023-02-28 广州医科大学附属第五医院 作为肝细胞癌标志物的inava
CN113512582A (zh) * 2021-04-15 2021-10-19 上海鸿准生物医药科技有限公司 Slc22a18在过敏变态反应性疾病与炎症性疾病中的应用
CN113307835B (zh) * 2021-04-21 2022-12-13 南通大学 一种siRNA及其在制备慢性疼痛治疗药物中的应用
EP4356136A1 (en) * 2021-06-13 2024-04-24 Technion Research & Development Foundation Limited Method for determining suitability to anti-tnf alpha therapy
WO2023158713A1 (en) * 2022-02-16 2023-08-24 Ampel Biosolutions, Llc Unsupervised machine learning methods

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434227A (en) 1982-02-08 1984-02-28 Abbott Laboratories Immunoassay for class specific immunoglobulin antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1261257A (en) 1984-09-19 1989-09-26 Helgi Valdimarsson Prognostic value of rheumatoid factor isotypes and their association with disease activity
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6139832A (en) 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
WO1996024668A1 (en) 1995-02-08 1996-08-15 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR19990022283A (ko) 1995-06-05 1999-03-25 벤슨 로버트 에이치. 인체 케모킨 베타-11 및 인체 케모킨 알파-1
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
PL339740A1 (en) 1997-09-12 2001-01-02 Biogen Kay - a novel immune system protein
EP1033134B8 (en) * 1997-10-29 2007-09-19 Otsuka Pharmaceutical Co., Ltd. Compositions inhibiting smooth muscle proliferation and method for the diagnosis of arteriosclerosis
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
IL144029A0 (en) 1999-01-07 2002-04-21 Zymogenetics Inc Soluble receptor br43x2 and methods of using
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1194167E (pt) 1999-06-09 2009-10-23 Immunomedics Inc Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b
RS51157B (sr) 1999-08-17 2010-10-31 Biogen Idec Ma Inc. Baff receptor (bcma), imunoregulatorni agens
DE10041402A1 (de) 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
CA2383773A1 (en) * 1999-09-01 2001-03-08 Boehringer Ingelheim Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7118872B2 (en) 2000-08-18 2006-10-10 Dyax Corp. Binding polypeptides for B lymphocyte stimulator protein (BLyS)
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2428242A1 (en) 2000-11-07 2002-05-16 Zymogenetics, Inc. Human tumor necrosis factor receptor
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
EE05294B1 (et) 2001-05-11 2010-04-15 Amgen Inc. TALL-1-ga seostuv ainekompositsioon
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA04001050A (es) 2001-08-03 2004-07-08 Genentech Inc Polipeptidos tacis y br3 y usos de los mismos.
US7256015B2 (en) 2001-09-21 2007-08-14 Amgen Inc. TALL-1 receptor molecules and uses thereof
WO2003035846A2 (en) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Structure of tall-1 and its cognate receptor
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
JP4498746B2 (ja) 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法
JP2005526501A (ja) 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP1532062B1 (en) 2002-07-18 2006-09-06 Fabio Perini S.p.A. Storage unit for elongated products
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
SE0300959D0 (sv) * 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
BRPI0411276A (pt) 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005029091A2 (en) * 2003-09-15 2005-03-31 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
DE102004016437A1 (de) 2004-04-04 2005-10-20 Oligene Gmbh Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20060024295A1 (en) 2004-06-04 2006-02-02 Genentech, Inc. Method for treating lupus
WO2006039238A2 (en) 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
EP1812060A2 (en) 2004-10-05 2007-08-01 Genentech, Inc. Method for treating vasculitis
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN101267836A (zh) * 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
CA2624359A1 (en) * 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
EP2005279A2 (en) 2006-03-15 2008-12-24 Koninklijke Philips Electronics N.V. Remote control pointing technology with roll detection
GB0607774D0 (en) 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
AU2007240355B2 (en) 2006-04-21 2013-09-26 Centocor, Inc. CXCL13 antagonists and their use for the treatment of inflammatory diseases
CA2652239A1 (en) * 2006-05-16 2007-11-29 Source Mdx Assessment of effect of an agent on a human biological condition using rodent gene expression panels
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
WO2008156494A1 (en) * 2006-11-03 2008-12-24 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
EP2084298A1 (en) 2006-11-09 2009-08-05 Institut National De La Sante Et De La Recherche Medicale Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
WO2008104608A1 (en) 2007-03-01 2008-09-04 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
JP2010523580A (ja) 2007-03-30 2010-07-15 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｃｘｃｌ１３アンタゴニストおよび炎症性疾患の処置のためのそれらの使用
AU2008232506A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to B-cell antagonists
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
BRPI0812461A2 (pt) 2007-06-08 2017-06-13 Biogen Idec Inc método de prever a resposta de um indivíduo a uma terapia, método de tratamento de um distúrbio imunológico, composição e kit
US20100261881A1 (en) 2007-09-03 2010-10-14 Protagen Ag Marker sequences for rheumatoid arthritis and use thereof
US20090202474A1 (en) * 2007-11-19 2009-08-13 Wyeth Expression of orphan gpr64 in inflammatory diseases
US8121883B2 (en) * 2008-02-07 2012-02-21 International Business Machines Corporation Method and system for automatically prioritizing opportunity based customer requirements
PE20120878A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
CA2772929A1 (en) 2009-09-03 2011-03-11 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Also Published As

Publication number Publication date
EP2473637A4 (en) 2013-05-01
HK1245341A1 (zh) 2018-08-24
JP2013503643A (ja) 2013-02-04
IN2012DN02485A (es) 2015-08-28
US8728730B2 (en) 2014-05-20
BR112012004777A2 (pt) 2019-09-24
EP3211094A2 (en) 2017-08-30
JP2021019594A (ja) 2021-02-18
US9822400B2 (en) 2017-11-21
EP2473637A1 (en) 2012-07-11
WO2011028945A1 (en) 2011-03-10
JP2017000141A (ja) 2017-01-05
RU2539112C2 (ru) 2015-01-10
JP5996429B2 (ja) 2016-09-21
CN107385034B (zh) 2021-08-17
CN107385034A (zh) 2017-11-24
RU2014145058A (ru) 2016-05-27
EP3211094A3 (en) 2017-11-01
JP6895718B2 (ja) 2021-06-30
US20110052488A1 (en) 2011-03-03
MX2012002766A (es) 2012-04-02
CA2772929A1 (en) 2011-03-11
KR20120104517A (ko) 2012-09-21
CN102597268B (zh) 2017-09-22
RU2012112822A (ru) 2013-10-10
EP2473637B1 (en) 2017-03-29
CN102597268A (zh) 2012-07-18
US20140341887A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
MX353186B (es) Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
WO2010036960A8 (en) Methods for treating, diagnosing, and monitoring lupus
MX353143B (es) Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
JO3131B1 (ar) مركبات كيميائية
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
TR201901930T4 (tr) Topraktaki mikrobiyal aktivitenin geliştirilmesine yönelik bir yöntem.
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
JO3766B1 (ar) منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
EP2529222A4 (en) MULTIPLE BIOMARKER PANELS FOR STRATIFYING ILLNESS HEAVY GRADES AND MONITORING THE TREATMENT OF DEPRESSIONS
IN2014CN04326A (es)
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
MX2010005395A (es) Metodo para tratar artritis.
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
WO2012019000A3 (en) Biomarkers for the identification monitoring and treatment of ovarian cancer
BR112015013771A2 (pt) biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina
MX351113B (es) Ensayo para capturar y detectar células circulantes de mieloma múltiple de la sangre.
EP2488187A4 (en) ASSAY FOR PREDICTING THE THERAPEUTIC EFFECT OF MECHANICAL CYCLES AND METHOD OF USE THEREOF
MX357429B (es) Predictores para el tratamiento del cáncer.
EP3839068A3 (en) Methods for treating, diagnosing, and monitoring lupus